Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy

OncoImmunology

Volumn 1, Issue 1, 2012, Pages 103-105

  Hubert, Pascale ^a,b   Amigorena, Sebastian ^a,b  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

Antibody dependant cell cytotoxicity; Cancer; Immunotherapy; Monoclonal antibody; Synapse

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FC RECEPTOR; MONOCLONAL ANTIBODY CHI TN; TRASTUZUMAB; TYROSINE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL KILLING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; EFFECTOR CELL; HUMAN; IN VIVO STUDY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84885366553     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.1.17963     Document Type: Note

References (10)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57; DOI:10.1038/nbt1137.
2. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6; DOI:10.1038/74704.
3. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII and FcgammaRIV. Blood 2008; 112:1205-13; DOI:10.1182/blood-2008-01-135160.
4. de Haij S, Jansen MJH, Boross P, Beurskens FJ, Bakema JE, Bos DL, et al. In vivo cytotoxicity of Type I CD20 antibodies critically depends on Fc receptor ITAM signalling. Cancer Res 2010; 70:3209-17; DOI:10.1158/0008-5472.CAN-09-4109.
5. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; DOI:10.1182/blood.V99.3.754.
6. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011; 71:5134-43; DOI:10.1158/0008-5472.CAN-10-4222.
7. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224:1198-206; DOI:10.1126/science.6729450.
8. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101:429-41; DOI:10.1172/JCI1348.
9. Fung PY, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990; 50:4308-14.
10. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; DOI:10.1038/nrclinonc.2010.223.